Oncopeptides AB (ONCO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oncopeptides AB (ONCO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8255
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oncopeptides AB (Oncopeptides) is a clinical development pharmaceutical company that offers development of oncology therapies to treat multiple myeloma. The company’s lead product candidate Ygalo (melflufen) is a peptidase potentiated cytotoxic drug and a potent anti-angiogenetic compound, among others. Its Ygalo is intended for the treatment of patients with late-stage relapsed and refractory multiple myeloma. Oncopeptides initiated an additional Phase II clinical trial of Ygalo in combination with dexamethasone. The company conducts Ygalo’s clinical study in collaboration with other institutions across the US and Europe including Dana-Farber Cancer Institute. Oncopeptides is headquartered in Stockholm, Sweden.

Oncopeptides AB (ONCO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncopeptides AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oncopeptides AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Oncopeptides Raises Funds Through Series A Financing 10
Equity Offering 12
Oncopeptides Raises USD19.5 Million in Private Placement of Shares 12
Oncopeptides Raises USD38.4 Million in Public Offering of Shares 13
Oncopeptides Raises USD84.3 Million in IPO 14
Oncopeptides AB – Key Competitors 15
Oncopeptides AB – Key Employees 16
Oncopeptides AB – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Financial Announcements 18
Jul 13, 2018: Oncopeptides: Interim report April-June 2018 18
May 17, 2018: Oncopeptides Interim report January – March 2018 19
Feb 22, 2018: Oncopeptides Year-end report 2017 20
Nov 15, 2017: Oncopeptides Interim Report July-September 2017 21
Aug 25, 2017: Oncopeptides: Interim Report April – June 2017 22
Corporate Communications 23
Aug 09, 2018: Anders Martin-Lof has been appointed as the new CFO of Oncopeptides 23
Mar 26, 2018: Oncopeptides Names Dr Christian Jacques As EVP Clinical Strategy And Chief Scientific Officer 24
Clinical Trials 25
Dec 10, 2017: Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo (melflufen) at the 59th Annual Meeting of ASH 25
Dec 09, 2017: Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo (melflufen) at the 59th Annual Meeting of ASH 26
Nov 07, 2017: Oncopeptides to attend the Jefferies Healthcare Conference in London on November 16th 27
Nov 01, 2017: Oncopeptides to present data from two clinical studies of Ygalo (melflufen) at American Society of Hematology, December 9-12. 28
Jun 14, 2017: First patient dosed in the pivotal phase III study OCEAN with Ygalo 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Oncopeptides AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncopeptides AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncopeptides AB, Deals By Therapy Area, 2012 to YTD 2018 8
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oncopeptides Raises Funds Through Series A Financing 10
Oncopeptides Raises USD19.5 Million in Private Placement of Shares 12
Oncopeptides Raises USD38.4 Million in Public Offering of Shares 13
Oncopeptides Raises USD84.3 Million in IPO 14
Oncopeptides AB, Key Competitors 15
Oncopeptides AB, Key Employees 16

List of Figures
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Oncopeptides AB (ONCO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mitsubishi Corporation:戦略・SWOT・企業財務分析
    Mitsubishi Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • TOA OIL Co Ltd (5008):企業の財務・戦略的SWOT分析
    Summary TOA OIL Co Ltd (TOA OIL), a subsidiary of Showa Shell Sekiyu KK is an oil and gas company that offers contract refining of crude oil. The company offers products such as diesel oil, coker naphtha scrubber, kerosene, polynaphtha units, LPG hydrofining unit, gasoline scrubber, and vacuum diese …
  • Prysmian SpA (PRY):電力:M&Aディール及び事業提携情報
    Summary Prysmian SpA (Prysmian) is a provider of cables and systems. It designs, develops, manufactures, supplies, and installs cables for a wide range of applications. The company produces high- and medium voltage cable systems; high and extra high voltage cables; optical fiber, optical cables, opt …
  • General Dynamics Corp (GD):企業の財務・戦略的SWOT分析
    General Dynamics Corp (GD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Tesco Corporation:石油・ガス:M&Aディール及び事業提携情報
    Summary Tesco Corp (Tesco), a subsidiary of Nabors Industries Ltd, is an oilfield technologies company. It sells and rents top drives and automated pipe handling equipment; and offers tubular services, including related products and accessories sales and aftermarket sales and services. The company o …
  • Bionik Laboratories Corp (BNKL):企業の財務・戦略的SWOT分析
    Summary Bionik Laboratories Corp (Bionik) is a medical device company that designs and develops transformational technologies, prosthetics and assisted robotic products and solutions. The company offers rehabilitation technology that senses patient movements and limitations. It provides lower body e …
  • Imerys SA:企業のM&A・事業提携・投資動向
    Imerys SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Imerys SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • The Macerich Co:企業のM&A・事業提携・投資動向
    The Macerich Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Macerich Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • APR Applied Pharma Research SA-医療機器分野:企業M&A・提携分析
    Summary APR Applied Pharma Research SA (APR) is a healthcare company which focuses on the development and licenses of healthcare products for rare therapeutic areas. The company offers consumer health products, prescription healthcare products and therapeutic products. APR’s product pipeline portfol …
  • Britannia Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Britannia Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Hera SpA (HER):企業の財務・戦略的SWOT分析
    Hera SpA (HER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Future Plc (FUTR):企業の財務・戦略的SWOT分析
    Summary Future Plc (Future) is a media company that offers media and digital business solutions various customers. The company offers its services in various areas such as technology, creative, photography and design, games, advertising and film and music. It provides licensing and syndication, expo …
  • Universal Health Services Inc (UHS):企業の財務・戦略的SWOT分析
    Universal Health Services Inc (UHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • SANUWAVE Health Inc (SNWV):企業の財務・戦略的SWOT分析
    Summary Sanuwave Health Inc (Sanuwave), formerly Rub Music Enterprises Inc, is a medical device company that develops and commercializes noninvasive biological response activating devices. The company's products portfolio include dermapace, which is used in the treatment of chronic and acute conditi …
  • Odakyu Electric Railway Co., Ltd.:企業の戦略・SWOT・財務情報
    Odakyu Electric Railway Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Odakyu Electric Railway Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • SVOGL Oil Gas and Energy Ltd:企業の戦略的SWOT分析
    SVOGL Oil Gas and Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Raytheon Co:企業のM&A・事業提携・投資動向
    Raytheon Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Raytheon Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Havfisk ASA:企業の戦略・SWOT・財務分析
    Havfisk ASA - Strategy, SWOT and Corporate Finance Report Summary Havfisk ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Concord Medical Services Holdings Ltd (CCM):企業の財務・戦略的SWOT分析
    Summary Concord Medical Services Holdings Ltd (CMS) is a diagnostic imaging center that offers clinical support services and laboratory services. The center offers radiotherapy and diagnostic imaging equipment services such as head gamma knife systems, body gamma knife systems and linear accelerator …
  • Ahli Bank Qsc:企業の戦略・SWOT・財務分析
    Ahli Bank Qsc - Strategy, SWOT and Corporate Finance Report Summary Ahli Bank Qsc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆